FDA officials gear up staff to follow "least burdensome" criteria through series of internal briefings
This article was originally published in Clinica
Stung by industry criticism, the US FDA has begun a concerted effort to prove that it is giving serious weight to the "least burdensome" provisions of the FDA Modernization Act of 1997 (FDAMA).
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.